Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NUBEQA vs ANDROID 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Androgen receptor inhibitor; binds to the androgen receptor and inhibits nuclear translocation, DNA binding, and recruitment of coactivators, thereby reducing prostate cancer cell proliferation.
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Treatment of patients with non-metastatic castration-resistant prostate cancer (nm CRPC),Treatment of patients with metastatic hormone-sensitive prostate cancer (m HSPC) in combination with docetaxel
Hypogonadism in males (primary and secondary),Delayed puberty in males,Metastatic breast cancer in women (as palliative therapy)
600 mg orally twice daily with food.
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
Terminal elimination half-life is approximately 20 hours; supports once-daily dosing.
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
Primarily metabolized by CYP3A4 and also by CYP2C8 and UGT1A1 to a lesser extent.
Primarily hepatic via reduction and oxidation; metabolites include androsterone and etiocholanolone; excreted in urine.
Primarily excreted as unchanged drug via feces (approximately 63.7%) and urine (approximately 23.8%); minimal biliary excretion.
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
Approximately 97% bound to plasma proteins (primarily albumin).
97–99% (sex hormone-binding globulin and albumin)
Apparent volume of distribution is approximately 98 L (1.2 L/kg for a 80 kg patient), indicating extensive tissue distribution.
0.3–0.6 L/kg; indicates distribution into lean muscle and sex organs
Absolute oral bioavailability is approximately 21% (fasted state); increased by 2.6-fold with a high-fat meal.
Oral: <5% (methyltestosterone: ~20–25% due to 17α-alkylation); IM: 100%
No dose adjustment required for GFR ≥30 m L/min. Not recommended for GFR <30 m L/min.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose or increasing interval; monitor for fluid retention and hypertension.
Child-Pugh A: No adjustment. Child-Pugh B: Not recommended. Child-Pugh C: Contraindicated.
Contraindicated in Child-Pugh class B or C cirrhosis. For mild hepatic impairment (Child-Pugh A), start with lower dose (e.g., 12.5 mg every 2 weeks) and titrate based on response and liver function.
Safety and efficacy not established; no recommended dose.
Not recommended for use in pediatric patients (safety and efficacy not established). For male adolescents with hypogonadism, individualize: start at 12.5 mg every 2 weeks and adjust based on testosterone levels and growth.
No dose adjustment required based on age alone; monitor for adverse effects.
Start with lower initial dose (e.g., 12.5 mg every 2 weeks); monitor prostate-specific antigen (PSA) and hematocrit frequently. Avoid in patients with prostate cancer or untreated sleep apnea.
None.
WARNING: Androgens are contraindicated in pregnancy due to masculinization of female fetus. Hepatotoxicity, including peliosis hepatis and hepatic neoplasms, has been reported with prolonged use.
Ischemic cardiovascular events,Hypertension,Fractures,Seizures,Posterior reversible encephalopathy syndrome (PRES),Hypersensitivity reactions,Fetal toxicity
Use with caution in patients with hepatic, renal, or cardiovascular disease; may cause gynecomastia, edema, hypercalcemia, and polycythemia; monitor liver function, lipid profile, and hematocrit periodically; may accelerate bone maturation in children; risk of prostate hypertrophy and urethral obstruction.
Pregnancy,Severe hepatic impairment (Child-Pugh C)
Known or suspected prostate cancer; male breast cancer; pregnancy; lactation; hypersensitivity to methyltestosterone; severe hepatic impairment.
Take with food to increase absorption; food with moderate-to-high fat content enhances bioavailability. Avoid grapefruit juice or products containing grapefruit as they may inhibit P-gp and increase darolutamide levels.
Take with food containing fat (e.g., avocado, nuts, olive oil) to enhance absorption. Avoid grapefruit juice as it may increase testosterone levels via CYP3A4 inhibition. Limit alcohol due to potential liver effects.
NUBEQA (darolutamide) is contraindicated in pregnancy. Based on its mechanism of action (androgen receptor inhibition), it can cause fetal harm. Animal studies have shown adverse developmental effects including embryotoxicity and malformations in rats at exposures below human clinical exposure. No adequate human data exist. It should not be used in pregnant women or those planning to become pregnant. If exposure occurs during pregnancy, the patient should be apprised of the potential hazard to the fetus.
Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure occurs before 12 weeks gestation. Second and third trimesters: Continued risk of female pseudohermaphroditism, and potential for masculinization of female external genitalia. Androgens can cross the placenta and may also cause skeletal abnormalities and growth retardation. Pregnancy category X.
It is unknown whether darolutamide or its metabolites are excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, breastfeeding should be discontinued during treatment with NUBEQA and for at least 1 week after the final dose. The milk-to-plasma ratio (M/P ratio) is not available.
Methyltestosterone is excreted into breast milk; M/P ratio not established. May cause virilization in female infants and premature sexual development in male infants. Androgens can suppress lactation. Use during breastfeeding is contraindicated.
No dosing adjustment recommendations are available for use during pregnancy because NUBEQA is contraindicated in pregnant women. There are no clinical data regarding the pharmacokinetic changes in pregnancy, and no studies have evaluated the need for dose adjustment in this population. Therefore, no specific dose adjustments for pregnancy are provided.
Android 25 is contraindicated in pregnancy, so no dosing adjustments are applicable. If used inadvertently, discontinue immediately. No pharmacokinetic data to guide dose changes; avoid use entirely.
NUBEQA (darolutamide) is a non-steroidal androgen receptor inhibitor with low blood-brain barrier penetration, reducing CNS side effects like falls and fractures. Monitor for cardiovascular events and hypertension; dose adjustment required in severe renal impairment (e GFR 15-29 m L/min) or moderate hepatic impairment (Child-Pugh B). Administer with food to enhance absorption. No dose adjustment for mild renal or hepatic impairment.
Android 25 (testosterone undecanoate) requires absorption via lymphatic system; administer with fat-containing meal. Monitor serum testosterone levels 3-5 hours post-dose. Avoid in patients with breast cancer or known or suspected prostate cancer. Risk of polycythemia; check hematocrit before and during therapy.
Take NUBEQA with food at the same time each day.,Swallow tablets whole; do not crush, chew, or split.,Do not take with strong P-glycoprotein (P-gp) inducers (e.g., rifampin) or inhibitors (e.g., ketoconazole).,Report unusual bleeding, bruising, or signs of bleeding (e.g., blood in urine or stool).,Use effective contraception during treatment and for 1 week after last dose if partner could become pregnant.,Inform your doctor if you have severe kidney or moderate liver problems.
Take capsules with meals, especially those containing fat, to improve absorption.,Do not chew or crush capsules; swallow whole.,Report signs of deep vein thrombosis (leg swelling, pain) or pulmonary embolism (sudden dyspnea, chest pain).,Women of reproductive potential should avoid pregnancy; use effective contraception.,Keep out of reach of children; testosterone can cause serious harm if accidentally ingested.,Regular blood tests (testosterone, hematocrit, PSA, lipid profile) are required.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NUBEQA vs ANDROID 25, answered by our medical review team.
NUBEQA is a Androgen Receptor Inhibitor that works by Androgen receptor inhibitor; binds to the androgen receptor and inhibits nuclear translocation, DNA binding, and recruitment of coactivators, thereby reducing prostate cancer cell proliferation.. ANDROID 25 is a Androgen that works by Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NUBEQA and ANDROID 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NUBEQA is: 600 mg orally twice daily with food.. The standard adult dose of ANDROID 25 is: Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NUBEQA and ANDROID 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NUBEQA is classified as Category C. NUBEQA (darolutamide) is contraindicated in pregnancy. Based on its mechanism of action (androgen receptor inhibition), it can cause fetal harm. Animal studies have shown adverse d. ANDROID 25 is classified as Category C. Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure oc. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.